Keywords: Wilex, UCB Pharma, MEK inhibitor WX-554

Germany’s Wilex gets UCB milestone by filing for Ph I of WX-554

Article | 05 August 2009

Print This

German biopharmaceutical firm Wilex has filed an application with the German Federal Institute for Drugs and Medical Devices (BfArM) for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in